Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study
Summary
Lantern Pharma said longer treatment with LP-300 improved outcomes for lung cancer patients in a phase 2 study. The headline points to clinical efficacy data rather than a corporate transaction or personnel move. This makes the item relevant to the pharma and life sciences software ecosystem because Lantern Pharma operates in drug development. The article does not provide details about a new software product, financing event, or acquisition.
Classifications
industries
HealthTech
applications
Data Management
AskAI Classifications
Labels
SaaS
AI/ML Platforms
Bioinformatics Software
Linked Companies
Lantern Pharma, Inc
$1M to $5M